mardi 9 janvier 2018

Onco Actu du 9 janvier 2018

1. Biologie

CRISPR hits a snag: Our immune systems may attack the treatment [STAT]

How the immune system could stymie some CRISPR gene therapies [Nature]

2. Etiologie

Female Night Shift Workers May Have Increased Risk of Common Cancers [AACR]

3.1 Prévention - Tabac

Drugs, gums or patches won’t increase your chances of quitting [The Conversation]

India top court sets aside order canceling larger tobacco health warnings [Reuters]

4. Dépistage, diagnostic et pronostic

Could finding more cancer lead us to understand risk factors less? [HealthNewsReview]

4.12 Biopsies liquides

Improved blood stabilization should expand use of circulating tumor cell profiling [Mass. General Hospital]

4.2 Dép., diag. & prono. - Génome

500,000 Britons’ Genomes Will Be Public by 2020, Transforming Drug Research [MIT Technology Review]

Drug Company Consortium To Sequence The Genes Of 500,000 Britons Over Next Two Years [Forbes]

4.9 Dép., diag. & prono. - Sein

Scientists identify breast cancer patients who may develop incurable secondary cancers [EurekAlert!]

5. Traitements

Last Month in Oncology with Dr. Bishal Gyawali: December 2017 [ecancernews]

5.12 Immunothérapies

Cracking Tumor Defiance [Harvard Medical School]

‘Immunomap’ Suggests More is Better When it Comes to Immune Cell Receptors and Patients’ Response to Immunotherapy [Johns Hopkins]

5.12.1 Immunothérapies - partenariats

Sanofi, Regeneron up the ante on PD-1 I/O program by a billion dollars [EndPoints]

5.12.5 Immunothérapies - Pharma

Merck’s KEYTRUDA® (pembrolizumab) Significantly Improved Recurrence-Free Survival Compared to Placebo as Adjuvant Therapy in Patients with Stage 3 Resected High-Risk Melanoma (EORTC1325/KEYNOTE-054) [Merck]

5.2.1 Pharma - Partenariats

Exelixis and StemSynergy Enter into Exclusive Licensing Agreement for the Discovery and Development of Novel Anticancer Therapies [Exelixis]

Pfizer Establishes New Partnering Model for Early-Stage Academic Research [Pfizer]

5.2.2 Pharma - Fusions & Acquisitions

$11 billion biotech binge fuels forecasts of 2018 M&A surge [Reuters]

Celgene's $7 Billion Purchase Is Great For Drug Inventors. Is It Great For Celgene? [Forbes]

5.9.4 AACR - poumon

Fostering New Advances in Lung Cancer Research [Cancer Research Catalyst]

6. Lutte contre les cancers

Acupuncture May Reduce Treatment-Related Joint Pain for Breast Cancer Patients [NCI]